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Abstract  Objective: To determine the risk factors that played roles in the incidence of multidrug-resistant tuberculosis (MDR-TB) in such patients. Multidrug-Resistant Tuberculosis is a form of tuberculosis caused by Mycobacterium tuberculosis that is resistant to at least isoniazid and rifampicin. 
 Methods: This was a case control study to compare MDR-TB to non-MDR-TB pulmonary tuberculosis outpatients in Dr. Hasan Sadikin General Hospital, Bandung on August–September 2014. Fifty MDR-TB outpatients were included as the cases and 50 non-MDR-TB outpatients as controls. Data was collected by questionnaires and patient’s registration forms. Bivariate and multivariate analyses were performed using chi-square test and multiple 
logistic regression test, with p<0.05 considered significant.  Results: From bivariate analysis, number of previous tuberculosis treatments, 
regularity of previous treatment, and burden of cost were significant risk factors for developing MDR-TB (p<0.05); while from multivariate analysis, number of previous TB treatments was the only risk factor that played a 
significant role in the incidence of MDR-TB (OR 24.128 95% CI 6.771-85,976).  Conclusions: Patients and medication factors are risk factors that play 
roles in the incidence of MDR-TB. The significant risk factor is the number of previous TB treatment.  Keywords: Multidrug-resistant tuberculosis, resistance, risk factors, tuberculosis
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IntroductionGlobal situation of tuberculosis (TB) is getting worse with increasing numbers of TB case year by year. Worldwide, the rate of TB incidence 
reduction remained at only 1.5% from 2014 to 2015 with a mortality rate of 100,000 cases 
at the end of 2015. Currently, Indonesia is in the second country with the highest burden of TB.1Another problem occurs when TB patients develop drug resistance. Multidrug resistant 
tuberculosis or known as MDR-TB is defined as a Mycobacterium tuberculosis infection that 
is resistant to at least two of the first line drug, i.e. isoniazid and rifampicin.2,3 Multidrug-resistant tuberculosis patients will have to take a new type of drug that is less effective, more complex, and also more expensive than the old regiment. Hence, the World Health 
Organization (WHO) declares MDR-TB as a threat for global health due to its high burden, both in social and economic aspects.1
In 2015, there were 480,000 new cases of MDR-TB worldwide. From all TB cases 
identified in Indonesia, 2.8% of the cases are 
primary MDR-TB while 16% of the cases are secondary MDR-TB. These numbers increase globally every year.1
Mycobacterium tuberculosis resistance can be triggered by multiple factors, both from the bacteria and human host.4–6 Therefore, the aim of this study was to explore the risk factors that play roles in the incidence MDR-
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TB in the population of patients in Dr. Hasan Sadikin General Hospital, Bandung, which is the highest health referral center in West Java. 
MethodsThis was a case-control observative analytical 
study performed at the Respirology and Critical 
Respiratory Care Division of the  Internal Medicine Department, Dr. Hasan Sadikin General Hospital during the period of August to September 2014. This study was approved 
by the Ethical Committee of Dr. Hasan Sadikin General Hospital Bandung. All TB patients who were on TB treatment during the study 
period were included in this study. Cases were collected from MDR-TB outpatients under 
Directly Observed Treatment, Short-course-
plus (DOTS-plus) treatment in MDR-TB clinic while controls were taken from pulmonary TB 
outpatients under Direct Observed Treatment, 
Short-course (DOTS) treatment in DOTS clinic.Based on the minimum sample requirement calculated by using Lemeshow formula, 100 samples (consisted of 50 cases and 50 controls) were recruited using the consecutive sampling method. The inclusion criteria for cases were patients who had been diagnosed as MDR-TB patients based on drug susceptibility test (DST) and GeneXpert. Meanwhile, patients 
who were confirmed as pulmonary TB patients based on either microbiological examination, smear test, chest X-ray, or other clinical means of diagnosis by experts were included as controls. Subjects who refused to participate were excluded. Data collected were number of previous TB treatments, regularity of previous treatment, cost burden, side effects, and communication, information, and education measures provided by health provider regarding TB, TB treatment, consequences from defaulting the treatment, and MDR-TB. A self-administered questionnaire that had been tested for validity and reliability were used to collect data. Subjects’ demography were collected from the patient registration form. Statistical analyses conducted included 
Chi-square test for bivariate analysis and multiple logistic regression for multivariate analysis. 
ResultsThe demographic characteristics of the study subjects were described (Table 1). Multidrug-
resistant tuberculosis patients were mostly 
men (66%) in their productive age, i.e. 14 to 54 
years old (44%). Many MDR-TB patients were 
unemployed at the time of the study (50%). The same situation was also seen in the control 
population (38%). In addition, the MDR-TB 
(64%) patients and their controls (70%) also did not have daily nor monthly income. Most MDR-TB patients used the national insurance 
(BPJS) to pay their treatment expenses (84%). A great proportion of the MDR-TB patients had 
their first TB treatment at the primary health 
care (puskesmas) setting (60%).The risk factors studied were factors that 
significantly correlated with the incidence of MDR-TB, including number of previous TB treatments (p=0.000), regularity of TB treatment (p=0.001), and also burden of cost (p=0.003).Multiple logistic regression was applied in the study (Table 3).  The p value for these 
factors was considered significant if p<0.05. Final regression showed that the only factor 
that played a significant role in the incidence of MDR-TB was the number of the previous TB 
treatments with and odd ratio (OR) of 24.128 
(confidence interval 95%, 6.771–85.976).
DiscussionMost of the MDR-TB patients in this study are men in productive age (Table 1). This is similar to the result of a study by Law et al.8 stating that many MDR-TB cases occur in 
patients with an average age of 48 years old. The same employment situation is also found for MDR-TB patients in this study and also in the study by Law et al.8 in which most patients are unemployed. The MDR-TB treatment which must be implemented daily at the hospital is the cause this situation.Results in this study show that most MDR-TB patients had experienced >2 previous TB treatments (Table 2). Such a high number is also found in various studies.6,8 From the perspective of the regularity of the previous treatment(s), it is revealed that there are 27 MDR-TB patients did not regularly consume the TB drugs during their previous treatment. The difference between the number of MDR-TB patients with regularl and irregular treatment is 4 patients with more patients performed irregular treatment. This slight difference can also be seen in a study concucted by Sarwani et 
al.9 For burden of cost, the majority of  MDR-TB patients felt that cost becomes a burden, with 
the ratio of 16:9. Similar numbers can also 
Role of Risk Factors in the Incidence of Multidrug-Resistant Tuberculosis
:57–63
International Journal of Integrated Health Sciences. 2017;5(2) 59
Alya Putri Khairani, Prayudi Santoso, et al. 
:57–63
Table 1 Characteristics of MDR-TB Patients and Their Controls
Characteristics
Categories
MDR-TB
(n=50) %
Non-MDR-TB
(n=50) (%)
Sex    Men 33 66 28 56   Women 17 34 22 44
Age (yrs.)   14–54 44 88 41 82
   ≥55 6 12 9 18
Occupation
   Civil servant 0 0 2 4   Private employee 2 4 4 8   Enterpreneur 11 22 8 16   Housewife 7 14 7 14   Labor/Farmer 3 6 0 0   Student 0 0 9 18   Unemployed 25 50 19 38
Income per month   <IDR 500,000 3 6 1 2   IDR 500,000–1,000.000 10 20 7 14   >IDR 1,000.000 5 10 7 14   None 32 64 35 70
Healthcare payment   National insurance (BPJS) 42 84 32 64   Insurance from workplace 0 0 4 4   Personal/Family 4 8 12 24
   Other party 0 0 2 4
   Others 4 8 2 4
Place to Receive First TB treatment   Primary Healthcare (puskesmas) 30 60 2 4
   Center for Lung Disease Treatment (BP4) 2 4 0 0   Dr. Hasan Sadikin General Hospital 2 4 42 84
   Other Government General Hospital 10 20 3 6   Private Hospital 2 4 2 4   Private Practice Doctor 4 8 1 2Note: yrs.= years; IDR= Indonesian rupiahs
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Table 2 Risk Factors that Played Roles in the Occurrence of MDR-TB in MDR-TB Patients
Factors MDR-TB n (%) Non-MDR-TBn (%) p Value
Number of previous TB treatment   1 8 (16) 42 (84) 0.000
   ≥2 42 (84) 8 (16)
Regularity of previous treatment   Regular 23 (46) 39 (78) 0.001   Irregular 27 (54) 11 (22)
Burden of cost   Yes 32 (64) 17 (34) 0.003   No 18 (36) 33 (66)
Side effects   Yes 32 (64) 23 (46) 0.070   No 18 (36) 27 (54)
Communication, information, education 
given by health officers
   Completely given 20 (40) 27 (54)
0.161   Incompletely given 30 (60) 23 (46)
be found for the side effects. This situation explained that factors related to the patients, i.e. regularity of previous treatment, burden of 
cost, and side effects) would provide sufficient differences in the high frequency distribution of the MDR-TB patients.10 Results from the questionnaires showed that some MDR-TB patients claimed that they had not received complete information on TB and MDR-TB. The complete information should include information on TB, TB treatment, consequences related to defaulting TB treatment, and MDR-TB. The health providers tend to forget to give 
information about MDR-TB. Nofizar et al.6 
showed the same finding. Health providers 
do explain about MDR-TB with 98% of MDR-TB patients in Persahabatan General Hospital, where the study was conducted, agreed to the statement.The risk factors that played roles in the incidence of MDR-TB in MDR-TB patients are described (Table 2). Previous TB treatment is a strong factor that plays a role in the incidence of MDR-TB. A study in Belarus has revealed that the risk of MDR-TB to occur in 
TB patients increased 6.1 times if the patients were under TB treatments before MDR-TB.11 
In Uganda, a study revealed that relapsed TB cases and failed TB treatment are associated with the occurrence of MDR-TB.12 Thus, it is possible that the number of TB treatment and the regularity of previous treatment affect the occurrence of MDR-TB.To study about the relationship between the number of previous TB treatments before MDR-TB and the incidence of MDR-TB, it is important to understand the quality of the 
TB treatment first. Good quality treatment shows an adequate treatment. An inadequate treatment provides more opportunities for the accumulation of individual mutations.13 The treatment will not be able to eradicate the mutated bacteria. This circumstance will make the TB patients receive more than one treatment. Eventually, resistance develops and MDR-TB occur.The regularity of TB treatment has a causal relationship with the occurrence of MDR-TB. Irregular treatment, meaning that there are occasions where patients do not take the TB drugs as instructed, could increase the risk of relapse and eventually cause MDR-TB.1,3,4 A study by Barroso et al.13 shows that irregularly treated patients has 7 times higher 
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risk to develop MDR-TB when compared to the regularly treated patients.13 Another study also shows the same conclusion.9 Results from the questionnaires in the present study shows variety of circumstances known to be the reason for patients to take the treatment irregularly, and even cause the patients to not completely follow the scheduled treatment. Those circumstances are (1) patients are busy with their daily activities that they forget to take their medicine, (2) patients feel better making them only take the medicine once in a while, (3) patients do not have money during the treatment. Same situations are found in a study by Jaggarajamma et al.14It follows that the number of previous TB treatments and the regularity of previous treatments are interrelated.13,15 An adequate 
TB treatment is defined as a treatment that follows the established rules, including the rule to take the medicine regularly. If the drugs are consumed irregularly, the treatment will be inadequate, hence it becomes a poor quality treatment. In the end, this may affect the number of TB treatments received and may lead to the occurence of MDR-TB.13 Similar pattern can be seen in this study.Burden of cost during TB treatment affects the incidence of MDR-TB. The costs that are incurred during treatment is also taken into considerations when TB patients considering whether to continue the treatment  during the course of treatment. Many patients decided to 
stop treatment due to the burden of cost. Hill et 
al.16 found the same situation in Gambia. There are many situations related tothe burden of cost during treatment that causes patients to default from treatment and contributes to the occurrence of MDR-TB. According to Wahab et 
al.17 one of the situations is the drug financing that is applied when TB treatment is obtained 
outside the DOTS program. However, this study found another situation. According to the MDR-TB patients, the burdens that they felt 
as the most difficult is the lost of working time and being unemployed during the treatment. Patients who are enterpreneurs and labors admitted that TB, MDR-TB, and their treatment disturb their work during the day and make them delay their work, especially during  the intensive months of treatment (1–2 months). In the meantime, patients do not receive daily nor monthly income as usual. Those situations 
make the financial burden more difficult to bear.16 Furthermore, due to the long period of TB treatment, transportation cost also becomes a heavy burden to the patients. Those problems are felt by both MDR-TB patients and their control.Result of this study shows that the side effects of the treatment do not play roles in the incidence of MDR-TB. This statement is supported by the fact that both groups are complaining about side effects during TB treatment. Although the side effects are disturbing, some patients are not bothered 
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Multiple Linear Regression Analysis and Estimation of Odds Ratio (OR) for the 
Risk Factors that Played Significant Roles to the Incidence of MDR-TB
Table 3
Variables coef B SE(B) p value Adj OR (CI 95%)
Initial regression modelNumber of previous TB treatment 3.183 0.648 0.000 24.128 (6.771–85.976)Regularity of previous treatment -0.102 0.659 0.877 0.903 (0.248–3.287)Burden of cost 0.509 0.564 0.367 1.663 (0.551–5.023)Side effects 0.260 0.567 0.646 1.297 (0.427–3.940)
Communication, information, education given by health 
officers
0.548 0.629 0.327 1.729 (0.579–5.168)
Final regression modelNumber of previous TB treatment 3.183 0.648 0.000 24.128 (6.771–85.976)
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by the effects and can continue the treatment without any obstacle. As a result, this study cannot prove the causal relationship between side effects and the incidence of MDR-TB. A previous study stated otherwise by stating that 
the side effects is a strong factor that influences the incidence of MDR-TB.10 Communication, information, and education given by the health provider do not have any causal relation with the occurrence of MDR-TB. The result of the questionnaires have shown that some MDR-TB patients and their controls did not receive information about MDR-TB and only received information regarding TB, its treatment, and the consequences from defaulting the 
TB treatment, which is incomplete. On the contrary, despite those problems, there are patients who still adhere well to the treatment. This situation shows that this incomplete communication, information, and education may lead to disappointment among patients and still reminds the patients to adhere with 
treatment. However, Nofizar et al.6 found the contrary with ninety percents of MDR-TB patients stated that the health provider did not communicate, educate, and give information regarding MDR-TB and they did not follow the treatment thoroughly.The results from the multivariate analysis show that of all possible risk factors that may 
influence the incidence of MDR-TB, the number of previous TB treatments is the only risk 
factor with is significant statistically (Table 
3). Patients with ≥2 previous TB treatments have a 24 times higher risk to obtain MDR-TB. This statement is also supported by studies by Barroso et al.13 and Zhao et al.7 in which patients who had received multiple treatments for tuberculosis are 13 times as likely to have MDR tuberculosis compared to those who had received only one prior treatment.Despite the fact that the number of previous TB treatments is strongly correlated with the regularity of previous treatment, multivariate analysis shows that the regularity of previous treatment is not a risk factor that plays a 
significant role in the incidence of MDR-TB. This result is also found in a study by Garcia Vázquez et al.18 If the MDR-TB patients had TB 
treatment(s) before the occurrence of MDR-TB, the patients will have at least a minimum risk to develop MDR-TB, even though the previous treatment was adequate.13,18 This situation can be explained as follow. In the 
first month of TB, patients might receive mutated Mycobacterium and become resistant to the treatment even before the treatment is started.7 This situation is called primary MDR-TB. The signs and symptoms of MDR-TB are not different from TB, making it common that patients with primary MDR-TB receive 
the usual first line TB treatment. In fact, any drug for susceptible-TB will not be effective to eliminate resistant Mycobacterium. The MDR-TB patients are likely to continue with the TB treatment, then move to the second line, until a screening for MDR-TB suspects is conducted.19,20 Nevertheless, Garcia Vázquez 
et al.18 stated that the risk of MDR-TB to occur by the factor of the number of previous TB treatments alone is minimum.Burden of cost is not one of the risk factors 
that play a significant role to the occurrence of MDR-TB. This study shows that most MDR-TB patients received previous TB treatment at the primary health center. Some of these patients stated that they went to the primary health center on foot. In primary health center, the TB treatment program is paid by the government, thus provided free of charge. This makes things easier for the patients. Although patients may 
have financial problems in other aspects, they can still go to the primary health center to receive treatment.The major limitations of this study is that the cases and controls were not ‘matched’ beforehand. In this study, the calculation of pharmacokinetic drug levels in the two groups of the samples are also not considered. In addition, comorbids are not taken into account.In conclusions, the risk factors to develop MDR-TB can come from patients themselves, including the regularity of the treatment and burden of cost, and can also be generated from the drug factor, which is the number of 
previous TB treatments. Of these, the number of previous TB treatments plays an important role in the incidence of MDR-TB.
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